Personalised treatment of patients with immune thrombotic thrombocytopenic purpura
Open Access
- 28 August 2025
- journal article
- abstracts
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (8) , 711-718
Abstract
Background. Treatment of immune thrombotic thrombocytopenic purpura (iTTP) includes plasma exchange (PEX) and immunosuppression (glucocorticoids and rituximab). The addition of caplacizumab to therapy has improved treatment outcomes in iTTP. However, the available therapies focus on the duration of drug administration and clinical response rather than ADAMTS13 activity. Aim. To evaluate the efficacy of therapy for iTTP targeting ADAMTS13 activity. Materials and methods. Treatment of patients with iTTP was started with PEX, prednisolone (1 mg/kg) and caplacizumab (10 mg/day). PEX was discontinued after an increase of platelet count 150×109/L. Only after PEX cessation treatment with rituximab (375 mg/m2 weekly) was started. Caplacizumab was discontinued when partial remission (ADAMTS13 20%) was achieved. Rituximab and glucocorticoids were discontinued when complete remission (ADAMTS13 40%) was achieved. Platelet count, schistocyte count, haemoglobin, haptoglobin, lactate dehydrogenase activity, ADAMTS13, ADAMTS13 inhibitor titre, number of PEX, plasma volume replaced, time to increase platelet count 150×109/L, achievement of partial and complete remission were analyzed. Data are presented as median and interquartile range. Results. From 2021 to 2025, the diagnosis of TTP was confirmed in 102 patients. 35 patients were included in the study. Platelet counts 150×109/L were achieved after 4 (3–5) PEX procedures in 4 (3–4.5) days. In total, 11 395 (7241–16 343) ml of plasma were exchanged. Partial remission was achieved in 100% of patients, the duration of caplacizumab therapy was 23 (12–30) days. Rituximab was administered from 4 to 8 times (median 4), complete remission was achieved in 33 out of 35 patients, 2 patients achieved only partial remission, they were treated with bortezomib and 1 with anti-CD38 monoclonal antibody. The probability of complete remission was 97.1%. Conclusion. The duration of therapy with caplacizumab, rituximab and glucocorticoids in patients with iTTP should be determined by the achievement of target ADAMTS13 activity.Keywords
This publication has 31 references indexed in Scilit:
- Tailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpuraBlood Vessels, Thrombosis & Hemostasis, 2024
- Does Caplacizumab for the management of thrombotic thrombocytopenic purpura increase the risk of relapse, exacerbation, and bleeding? An updated systematic review and meta‐analysis based on revised criteria by the International Working Group for thrombotic thrombocytopenic purpuraeJHaem, 2023
- Caplacizumab use for immune thrombotic thrombocytopenic purpura: the Milan thrombotic thrombocytopenic purpura registryResearch and Practice in Thrombosis and Haemostasis, 2023
- Five years of caplacizumab – lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpuraJournal of Thrombosis and Haemostasis, 2023
- Improved survival of patients with primary plasma cell leukemia with VRd or daratumumab‐based quadruplets: A multicenter study by the Greek myeloma study groupAmerican Journal of Hematology, 2023
- NICE guidance on caplacizumab for treating acute acquired thrombotic thrombocytopenia purpuraThe Lancet Haematology, 2021
- Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicineResearch and Practice in Thrombosis and Haemostasis, 2018
- Bethesda Assay for Detecting Inhibitory Anti-ADAMTS13 Antibodies in Immune-Mediated Thrombotic Thrombocytopenic PurpuraTH Open, 2018
- Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future researchJournal of Clinical Apheresis, 2013
- Rituximab therapy for thrombotic thrombocytopenic purpura: A proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune‐mediated disordersJournal of Clinical Apheresis, 2006